First randomized trial of tirzepatide in PCOS reports menstrual and pregnancy gains

A new randomized trial has tested tirzepatide, the drug sold in the United States as Mounjaro or Zepbound, as an add-on treatment for polycystic ovary syndrome (PCOS). The study, published in Diabetes, Obesity and Metabolism, found that overweight or obese women who took low-dose tirzepatide with metformin lost far more weight and were more likely to see their periods return and become pregnant than women who took metformin alone ^[1].

The trial enrolled 60 overweight or obese Chinese women with PCOS. Half were randomly assigned to metformin alone (1000 mg twice daily), and half received the same metformin dose plus tirzepatide at 5 mg once a week, for 16 weeks ^[1]. After 16 weeks, the combination group lost an average of 10.4 kg, compared with 1.7 kg in the metformin-only group ^[1]. Body mass index dropped by 4.12 points in the combination group versus 0.68 points in the metformin-only group ^[1]. Visceral fat, the fat around internal organs linked to metabolic disease, shrank by 34.13 square centimeters in the combination group compared with 4.67 square centimeters in the metformin group ^[1].

Beyond weight and fat measures, the combination group also showed greater improvements in reproductive hormone levels and other metabolic and endocrine markers ^[1]. Menstrual cycle recovery was significantly more common in the group taking both drugs, and total pregnancy rates were also higher ^[1]. After the 16-week treatment phase, everyone was switched to metformin alone, and researchers tracked pregnancy outcomes between weeks 25 and 48, with participants using barrier contraception for the first eight weeks of that follow-up period ^[1].

The researchers note that PCOS affects an estimated 11% to 13% of women of reproductive age worldwide and is a leading cause of ovulatory infertility ^[1]. Insulin resistance and obesity often make the condition worse, and metformin, while commonly used, has limited effectiveness on its own ^[1]. The study authors point to earlier research suggesting that GLP-1 receptor agonists combined with metformin can outperform metformin alone for weight loss, insulin sensitivity, and menstrual cycle restoration in women with PCOS ^[1].

Why it matters for patients

PCOS is common, and many women with the condition are also overweight or obese, which can worsen symptoms like irregular periods and reduce the odds of pregnancy. This trial is described as the first randomized study to test tirzepatide specifically in PCOS, adding to earlier work on other GLP-1 drugs like semaglutide and liraglutide in the same condition ^[1]. For patients weighing treatment options with their doctors, the results suggest a possible added benefit for menstrual regularity and pregnancy chances beyond what metformin alone offers, though the study does not show whether tirzepatide would work the same way in women who are not overweight or obese, since everyone enrolled had excess weight ^[1].

The trial has real limits. It was open-label, meaning participants and researchers knew who was getting which treatment, which can influence how outcomes like menstrual recovery are reported or measured. It included only 60 women, all in China, over just 16 weeks of active treatment ^[1]. Small, short, unblinded trials like this one are useful for generating hypotheses, but they are not enough on their own to establish that tirzepatide is safe or effective for PCOS in the broader population, including women in the United States taking Mounjaro or Zepbound for other approved uses.

What happens next

The trial registration listed is ChiCTR2400090908 ^[1]. The sources provided do not describe any follow-up studies, larger trials, or regulatory reviews planned for tirzepatide's use in PCOS specifically. Larger, longer, and blinded trials would be needed before conclusions could extend beyond this initial group of overweight and obese Chinese women, and that kind of research is not yet described in the available sources.